Epidemiology and Pathogenesis of Myelodysplastic Syndrome

Abstract Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal hematopoiesis (CH) to CH of indeterminate potential, clonal cytopenia of unknown significance, to frank MDS. The molecular heterogeneity seen in MDS is highly complex and includes mutations of genes involved in splicing machinery, epigenetic regulation, differentiation, and cell signaling. Recent advances in the understanding of the molecular landscape of MDS have led to the development of improved risk assessment tools and novel therapies. Therapies targeting the underlying pathophysiology will hopefully further expand the armamentarium of MDS therapeutics, bringing us closer to a more individualized therapeutic approach based on the unique molecular profile of each patient and eventually improving the outcomes of patients with MDS. We review the epidemiology of MDS and the newly described MDS precursor conditions CH, CH of indeterminate potential, and CCUS. We then discuss central aspects of MDS pathophysiology and outline specific strategies targeting hallmarks of MDS pathophysiology, including ongoing clinical trials examining the efficacy of these therapeutic modalities.

[1]  D. Neuberg,et al.  Prediction of risk for myeloid malignancy in clonal hematopoiesis. , 2022, NEJM evidence.

[2]  A. Wei,et al.  Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. , 2022, The Lancet. Haematology.

[3]  G. Garcia-Manero,et al.  A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes , 2022, American journal of hematology.

[4]  Weili Cai,et al.  The Biological and Clinical Consequences of RNA Splicing Factor U2AF1 Mutation in Myeloid Malignancies , 2022, Cancers.

[5]  A. Zeidan,et al.  CHIPing away the progression potential of CHIP: A new reality in the making. , 2022, Blood reviews.

[6]  H. Deeg,et al.  Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  K. Metzeler,et al.  Phase 1/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia or lyelodysplastic syndrome. , 2022, Journal of Clinical Oncology.

[8]  W. Liu,et al.  In Vivo Anti-Tumor Effect of PARP Inhibition in IDH1/2 Mutant MDS/AML Resistant to Targeted Inhibitors of Mutant IDH1/2 , 2022, Leukemia.

[9]  T. Bowman,et al.  Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations , 2022, bioRxiv.

[10]  S. Gore,et al.  Agent Orange and dioxin-induced myeloid leukemia: a weaponized vehicle of leukemogenesis , 2022, Leukemia & lymphoma.

[11]  P. D. Dal Cin,et al.  TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML , 2022, Blood advances.

[12]  Somnath Ghosal,et al.  DNA methylation: a saga of genome maintenance in hematological perspective , 2022, Human Cell.

[13]  P. Nguyen,et al.  Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.

[14]  L. Abrahmsén,et al.  Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ) , 2021, Nature Communications.

[15]  E. Clappier,et al.  Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group , 2021, Blood.

[16]  D. Neuberg,et al.  Inhibition of ATR with AZD6738 (Ceralasertib) for the Treatment of Progressive or Relapsed Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: Safety and Preliminary Activity from a Phase Ib/II Study , 2021, Blood.

[17]  M. Troadec,et al.  TP53 in Myelodysplastic Syndromes , 2021, Cancers.

[18]  D. Tiblalexi,et al.  PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome , 2021, Blood advances.

[19]  Yosuke Tanaka,et al.  A histone modifier, ASXL1, interacts with NONO and is involved in paraspeckle formation in hematopoietic cells. , 2021, Cell reports.

[20]  Z. Ge,et al.  Comparison Between Decitabine and Azacitidine for Patients With Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndrome: A Systematic Review and Network Meta-Analysis , 2021, Frontiers in Pharmacology.

[21]  I. Flinn,et al.  Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms , 2021, Leukemia.

[22]  H. Kantarjian,et al.  Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes , 2021, Cancer.

[23]  M. Konopleva,et al.  Phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS). , 2021 .

[24]  L. Nezi,et al.  TERT promoter mutations and melanoma survival: a comprehensive literature review and meta-analysis. , 2021, Critical reviews in oncology/hematology.

[25]  T. Haferlach,et al.  A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms. , 2020, Blood cancer discovery.

[26]  Benjamin L. Ebert,et al.  Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes , 2019, Nature Medicine.

[27]  S. Carr,et al.  Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML , 2020, JCI insight.

[28]  Wan-Jen Hong,et al.  Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study , 2020 .

[29]  E. Vellenga,et al.  Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Cazzola Myelodysplastic Syndromes. , 2020, The New England journal of medicine.

[31]  M. Mukherji,et al.  Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia , 2020, Communications biology.

[32]  A. Viale,et al.  Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes , 2020, Nature Medicine.

[33]  P. Campbell,et al.  SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS , 2020, Blood.

[34]  P. Glazer,et al.  Oncometabolites suppress DNA repair by disrupting local chromatin signalling , 2020, Nature.

[35]  B. Shuch,et al.  Oncometabolites suppress DNA repair by disrupting local chromatin signaling , 2020, Nature.

[36]  P. Campbell,et al.  SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM). , 2020, Blood.

[37]  L. Gondek,et al.  The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing. , 2020, Blood advances.

[38]  R. Collins,et al.  Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. , 2020, The Lancet. Haematology.

[39]  P. Vyas,et al.  SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications , 2020, Leukemia.

[40]  L. Shih,et al.  DNMT3A mutants provide proliferating advantage with augmentation of self-renewal activity in the pathogenesis of AML in KMT2A-PTD-positive leukemic cells , 2020, Oncogenesis.

[41]  M. Cazzola,et al.  Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. , 2020, The New England journal of medicine.

[42]  Dannie Durand,et al.  Family , 2006, Death in the Modern World.

[43]  Jie Jin,et al.  Impact of mutational variant allele frequency on prognosis in myelodysplastic syndromes. , 2020, American journal of cancer research.

[44]  H. Kantarjian,et al.  Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia , 2019, Cancer.

[45]  Y. Shyr,et al.  The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome , 2019, Blood.

[46]  T. Stricker,et al.  Variable Response to BCL2 Inhibition in MDS Is Enhanced across MDS Subtypes with Synergistic Combination of BCL2+MCL1 Inhibition , 2019, Blood.

[47]  B. Ebert,et al.  Myelodysplastic syndromes (MDS) occurring in Agent Orange exposed individuals carry a mutational spectrum similar to that of de novo MDS , 2019, Leukemia & lymphoma.

[48]  B. Ebert,et al.  Clonal hematopoiesis in human aging and disease , 2019, Science.

[49]  M. Gounder,et al.  METEOR-1: A phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours , 2019, Annals of Oncology.

[50]  B. Ebert,et al.  CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice. , 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[51]  N. Hosono Genetic abnormalities and pathophysiology of MDS , 2019, International Journal of Clinical Oncology.

[52]  FDA approves ivosidenib as first-line treatment for AML with IDH1 mutation , 2019, Case Medical Research.

[53]  K. Pradhan,et al.  U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies , 2019, Nature Cell Biology.

[54]  A. Ashworth,et al.  A requirement for STAG2 in replication fork progression creates a targetable synthetic lethality in cohesin-mutant cancers , 2019, Nature Communications.

[55]  Xiaomei Ma,et al.  Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. , 2019, Blood reviews.

[56]  P. Fenaux,et al.  Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. , 2019, Blood.

[57]  S. Jaiswal,et al.  Clonal hematopoiesis: Pre‐cancer PLUS , 2019, Advances in cancer research.

[58]  Jiqiang Yao,et al.  Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) , 2018, Blood.

[59]  D. Steensma Clinical consequences of clonal hematopoiesis of indeterminate potential. , 2018, Blood advances.

[60]  A. Shilatifard,et al.  TET2 coactivates gene expression through demethylation of enhancers , 2018, Science Advances.

[61]  Y. Xiong,et al.  SNIP1 Recruits TET2 to Regulate c-MYC Target Genes and Cellular DNA Damage Response , 2018, Cell reports.

[62]  R. Ohgami,et al.  del (5q) solely in Myelodysplastic syndrome , 2018, Atlas of Genetics and Cytogenetics in Oncology and Haematology.

[63]  B. Ebert,et al.  Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations. , 2018, Cancer cell.

[64]  M. Walter,et al.  Spliceosome Mutations Induce R Loop-Associated Sensitivity to ATR Inhibition in Myelodysplastic Syndromes. , 2018, Cancer research.

[65]  M. Warmuth,et al.  H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers , 2018, Nature Medicine.

[66]  C. Shao,et al.  The Augmented R-Loop Is a Unifying Mechanism for Myelodysplastic Syndromes Induced by High-Risk Splicing Factor Mutations. , 2018, Molecular cell.

[67]  J. Maciejewski,et al.  IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors , 2018, Clinical Cancer Research.

[68]  Kenneth D. Doig,et al.  ASXL1 c.1934dup;p.Gly646Trpfs*12—a true somatic alteration requiring a new approach , 2017, Blood Cancer Journal.

[69]  Kenneth D. Doig,et al.  ASXL1 c.1934dup;p.Gly646Trpfs*12—a true somatic alteration requiring a new approach , 2017, Blood Cancer Journal.

[70]  R. Wells,et al.  Tet2 restrains inflammatory gene expression in macrophages. , 2017, Experimental hematology.

[71]  O. Abdel-Wahab,et al.  Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression , 2017, Cell.

[72]  R. Deberardinis,et al.  Ascorbate regulates haematopoietic stem cell function and leukaemogenesis , 2017, Nature.

[73]  Q. Song,et al.  Telomerase reverse transcriptase promotes chemoresistance by suppressing cisplatin-dependent apoptosis in osteosarcoma cells , 2017, Scientific Reports.

[74]  M. Cazzola,et al.  Clinical significance of somatic mutation in unexplained blood cytopenia. , 2017, Blood.

[75]  T. Graubert,et al.  Functions of Replication Protein A as a Sensor of R Loops and a Regulator of RNaseH1. , 2017, Molecular cell.

[76]  D. Neuberg,et al.  Prognostic Mutations in Myelodysplastic Syndrome after Stem‐Cell Transplantation , 2017, The New England journal of medicine.

[77]  Gregory A. Breuer,et al.  2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity , 2017, Science Translational Medicine.

[78]  B. Ebert,et al.  The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia , 2016, Nature Reviews Cancer.

[79]  M. Warmuth,et al.  H3B-8800, an Orally Bioavailable Modulator of the SF3b Complex, Shows Efficacy in Spliceosome-Mutant Myeloid Malignancies , 2016 .

[80]  B. Dumitriu,et al.  Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS , 2016, British journal of haematology.

[81]  R. Bellazzi,et al.  Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[83]  S. Nahas,et al.  Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes , 2016, Leukemia.

[84]  L. Abrahmsén,et al.  Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy , 2016, Front. Oncol..

[85]  W. Wodzig,et al.  Ascorbic acid serum levels are reduced in patients with hematological malignancies , 2016, Results in immunology.

[86]  H. Kantarjian,et al.  IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression , 2015, Leukemia.

[87]  P. Campbell,et al.  SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. , 2015, Blood.

[88]  B. Ebert,et al.  Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. , 2015, Blood.

[89]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[90]  Kim Nasmyth,et al.  Closing the cohesin ring: Structure and function of its Smc3-kleisin interface , 2014, Science.

[91]  S. Gabriel,et al.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.

[92]  D. Neuberg,et al.  Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  Lili Yang,et al.  Telomerase, hTERT and splice variants in patients with myelodysplastic syndromes. , 2014, Leukemia research.

[94]  Christopher A. Miller,et al.  The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. , 2014, Cancer cell.

[95]  A. Grinberg,et al.  Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis , 2014, Nature Medicine.

[96]  C Haferlach,et al.  Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.

[97]  M. Cazzola,et al.  The genetic basis of myelodysplasia and its clinical relevance. , 2013, Blood.

[98]  M. Stratton,et al.  Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.

[99]  Sanjeeva Srivastava,et al.  Cohesin: Functions beyond sister chromatid cohesion , 2013, FEBS letters.

[100]  Y. Xiong,et al.  R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis. , 2013, Cancer cell.

[101]  Masao Nagasaki,et al.  Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms , 2012, Nature Genetics.

[102]  L. Rushton,et al.  Myelodysplastic Syndrome and Benzene Exposure Among Petroleum Workers: An International Pooled Analysis , 2012, Journal of the National Cancer Institute.

[103]  Iannis Aifantis,et al.  ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. , 2012, Cancer cell.

[104]  I. Weissman,et al.  The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. , 2012, Current opinion in immunology.

[105]  P. Hieter,et al.  Synthetic Lethality of Cohesins with PARPs and Replication Fork Mediators , 2012, PLoS genetics.

[106]  Zhimin Chen,et al.  Human telomerase reverse transcriptase transfection reduces apoptosis in human penile smooth muscle cells and slows down cellular aging. , 2012, The journal of sexual medicine.

[107]  A. Tefferi,et al.  Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients , 2011, Leukemia.

[108]  Peter J Campbell,et al.  Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms , 2011, Blood.

[109]  M. Björkholm,et al.  Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  P. Opolon,et al.  TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. , 2011, Cancer cell.

[111]  O. Abdel-Wahab,et al.  Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. , 2011, Cancer cell.

[112]  D. Neuberg,et al.  Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.

[113]  C. Cogle,et al.  Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. , 2011, Blood.

[114]  B. Quesnel,et al.  Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias , 2011, Leukemia.

[115]  Benjamin L Ebert,et al.  Unraveling the molecular pathophysiology of myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  D. Preston,et al.  Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  R. Arceci Chronic Immune Stimulation Might Act As a Trigger for the Development of Acute Myeloid Leukemia or Myelodysplastic Syndromes , 2011 .

[118]  M Cazzola,et al.  Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells , 2010, Leukemia.

[119]  M. Cazzola,et al.  Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia , 2010, Leukemia.

[120]  T. Economopoulos,et al.  Cell cycle and apoptosis regulatory gene expression in the bone marrow of patients with de novo myelodysplastic syndromes (MDS) , 2010, Annals of Hematology.

[121]  D. Birnbaum,et al.  TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). , 2009, Blood.

[122]  Sui Huang Faculty Opinions recommendation of An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. , 2009 .

[123]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[124]  I. Weissman,et al.  CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis , 2009, Cell.

[125]  W. Hahn,et al.  An RNA dependent RNA polymerase formed by hTERT and the RNase MRP RNA , 2009, Nature.

[126]  Federica Briatore,et al.  Increase of telomerase activity and hTERT expression in myelodysplastic syndromes , 2009, Cancer biology & therapy.

[127]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[128]  C. O'keefe,et al.  Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. , 2009, Blood.

[129]  A. Tefferi,et al.  Myelodysplastic syndromes. , 2009, The New England journal of medicine.

[130]  J. Shay,et al.  Actions of human telomerase beyond telomeres , 2008, Cell Research.

[131]  E. Andreakos,et al.  Toll-like Receptor-4 Is Up-Regulated in Hematopoietic Progenitor Cells and Contributes to Increased Apoptosis in Myelodysplastic Syndromes , 2007, Clinical Cancer Research.

[132]  Victor V Lobanenkov,et al.  Dual role of DNA methylation inside and outside of CTCF-binding regions in the transcriptional regulation of the telomerase hTERT gene , 2007, Nucleic acids research.

[133]  F. Askin,et al.  Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. , 2007, Blood.

[134]  J. Herman,et al.  hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site. , 2007, Cancer research.

[135]  J. Rutka,et al.  Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[136]  R. Humphries,et al.  Characterization of Asxl1, a murine homolog of Additional sex combs, and analysis of the Asx-like gene family. , 2006, Gene.

[137]  M. Blasco Telomeres and human disease: ageing, cancer and beyond , 2005, Nature Reviews Genetics.

[138]  W. Hahn,et al.  The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[139]  E. Estey,et al.  Risk factors of myelodysplastic syndromes: a case–control study , 2005, Leukemia.

[140]  M. Valentine,et al.  Telomerase expression predicts unfavorable outcome in osteosarcoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[141]  K. Flanders,et al.  Loss of Smad3 in acute T-cell lymphoblastic leukemia. , 2004, The New England journal of medicine.

[142]  Axel Hoos,et al.  Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[143]  H. Kreipe,et al.  Different expression levels of the telomerase catalytic subunit hTERT in myeloproliferative and myelodysplastic diseases. , 2004, Leukemia research.

[144]  H. K. Jeon,et al.  Ectopic Expression of the Catalytic Subunit of Telomerase Protects against Brain Injury Resulting from Ischemia and NMDA-Induced Neurotoxicity , 2004, The Journal of Neuroscience.

[145]  F. Bosman,et al.  Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity , 2002, International journal of cancer.

[146]  N. Harris,et al.  The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.

[147]  C. Preudhomme,et al.  Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France , 2001, British journal of haematology.

[148]  G. Mufti,et al.  The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. , 2000, Blood.

[149]  R. Weinberg,et al.  Methylation of the human telomerase gene CpG island. , 2000, Cancer research.

[150]  R. Davis,et al.  Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression. , 1998, Leukemia research.

[151]  T. Hirano,et al.  Identification of Xenopus SMC protein complexes required for sister chromatid cohesion. , 1998, Genes & development.

[152]  P. Venugopal,et al.  Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. , 1996, International journal of hematology.

[153]  H. Preisler,et al.  Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis , 1995, American journal of hematology.